Epigenetic Modulation of Amyloid Beta-resistant Synapses in Non-demented Subjects with Alzheimer's Neuropathology
Epigenetic Modulation of Amyloid Beta-resistant Synapses in Non-demented Subjects with Alzheimer's Neuropathology
批准号:
9396939
负责人:
Olga Zolochevska Cain
金额:
$3.21万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-21 至 2019-07-20
关键词:
AchievementAddressAffectAgeAlzheimer&aposs DiseaseAmyloid beta-ProteinBindingBiological PreservationBrainCause of DeathClinicalCognitiveDataDementiaDevelopmentDiseaseElectrophysiology (science)Enzyme-Linked Immunosorbent AssayEpigenetic ProcessEvaluationFlow CytometryFoundationsFunctional disorderFutureGoalsHippocampus (Brain)Impaired cognitionImpairmentIn VitroIndividualInjectableKnowledgeLaboratoriesLearningLesionLong-Term PotentiationMaintenanceMeasuresMemory LossMicroRNAsMolecular Biology TechniquesMusNeurodegenerative DisordersNeurofibrillary TanglesNeuronsNeurosciencesPathologyPatientsPharmacologyPresynaptic TerminalsProteinsProteomicsReportingResearchResearch PersonnelResistanceRoleSliceSymptomsSynapsesSynaptosomesTechniquesTestingTg2576Toxic effectTrainingWestern BlottingWild Type MouseWorkabeta accumulationabeta oligomerabeta toxicityage relatedcareercognitive abilitycognitive functiondementeddensitydesigneffective therapyexperimental studyextracellularhyperphosphorylated tauimprovedin vivoin vivo Modelinhibitor/antagonistinnovationneuropathologynon-dementednovelpreventresponseskillssynaptic functiontau aggregationtreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Several groups, including ours, have independently reported that certain individuals, here termed Non-
Demented individuals with Alzheimer’s Neuropathology (NDAN), remain cognitively intact despite the presence
of typical Alzheimer’s Disease (AD) neuropathology – extracellular amyloid beta (Aβ) aggregates and
hyperphosphorylated tau-containing intracellular neurofibrillary tangles (NFTs). The main goal of our research
is to unveil the yet unknown mechanisms responsible for preservation of cognitive function in NDAN in order to
develop novel effective therapies to treat AD, which will be centered on inducing cognitive resistance in anyone
affected by AD. Synaptic dysfunction due to the disrupting binding of toxic small Aβ and tau oligomers is one of
the earliest impairments in AD, believed to drive initial cognitive decline and ultimately clinical manifestation of
the disease. In previous work we found that synapses of NDAN subjects are resistant to the dysfunctional
binding of toxic A oligomers, a previously unappreciated phenomenon consistent with their evading clinical
manifestation of AD. In order to gain a more comprehensive understanding of synaptic resistance to Aβ
oligomers in NDAN individuals, we further performed proteomics of post-synaptic density (PSD) fractions of
hippocampi of control (non-demented, age-matched), AD and NDAN and determined that the PSD of NDAN
subjects has a unique protein signature, consistent with their unique ability to reject the toxic Aβ oligomers.
Through the predictive analysis of these proteomic data, specific miRNAs were identified as potential
regulators of the unique protein signature observed at NDAN PSD. In the present project, which is the next
step toward achieving our main research goal, we will use ex-vivo and in-vivo models to determine whether
these selected miRNAs allow synapses to acquire resistance to Aβ oligomer binding and toxicity. The
extensive training I will receive while completing this project will advance my knowledge of neuroscience, and
in particular Alzheimer’s Disease, my overall research skills and will help me become more intellectually
mature. It will also allow me to learn additional experimental techniques, particularly electrophysiology,
improving my skills and preparing me for the next step in the pursuing of a future career as an independent
researcher.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金